HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

multidrug resistance-associated protein 2

Subscribe to New Research on multidrug resistance-associated protein 2

multidrug resistance-associated protein; mutations in the gene for this protein are associated with Dubin-Johnson syndrome (JAUNDICE, CHRONIC IDIOPATHIC); RefSeq NM_000392 (human)

Also Known As:

ABCC2 protein; ABCC2 protein, human; ATP-binding cassette, sub-family C (CFTR/MRP), member 2 protein, human; CMOAT transport protein; CMOAT1 protein, human; MRP2 protein, multidrug resistance; MRP2 transport protein; cMOAT; cMOAT protein; canalicular multispecific organic anion transporter; hMRP2 protein; human MRP2 protein; multidrug resistance protein Mrp2

Networked: 186 relevant articles (3 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sugiyama, Yuichi: 8 articles (11/2010 - 05/2002)
2.	Brouwer, Kim L R: 7 articles (07/2014 - 09/2007)
3.	Roma, Marcelo G: 7 articles (03/2014 - 08/2003)
4.	Crocenzi, Fernando A: 7 articles (03/2014 - 08/2003)
5.	Mottino, Aldo D: 6 articles (02/2014 - 08/2003)
6.	Zucchetti, Andrés E: 5 articles (03/2014 - 12/2008)
7.	Sánchez Pozzi, Enrique J: 5 articles (02/2014 - 12/2008)
8.	Lage, Hermann: 5 articles (03/2013 - 01/2003)
9.	Suzuki, Hiroshi: 5 articles (02/2013 - 05/2002)
10.	Liu, Can: 4 articles (12/2014 - 08/2012)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 07/01/2014 - "This study evaluated the impact of impaired transport of breast cancer resistance protein (Bcrp) and multidrug resistance-associated protein 2 (Mrp2) on the hepatobiliary disposition of generated metabolites, TS and TGZ glucuronide (TG). " 09/01/2009 - "The objective of this study was to determine an appropriate culture period to assess whether a compound of interest is transported by efflux transporters such as human multidrug resistance 1 (hMDR1), human multidrug resistance-associated protein 2 (hMRP2), and human breast cancer resistance protein (hBCRP) in Caco-2 cells. " 09/01/2008 - "The renal apical transport transport of zonampanel was examined in this study using HEK293 cells expressing human organic anion transporter 4 (OAT4/SLC22A11), and membrane vesicles prepared from Sf-9 insect cells expressing human multidrug resistance-associated protein 2 (MRP2/ABCC2), MRP4 (ABCC4), and breast cancer resistance protein (BCRP/ABCG2). " 07/01/2008 - "The cumulative uptake study of radiolabeled substrates revealed that the function of canalicular efflux transporters such as bile salt export pump, multidrug resistance-associated protein 2, breast cancer resistance protein, and multidrug resistance 1 was adequately maintained in SCRH. " 06/01/2005 - "The objective of this study was to determine the role of the intestinal efflux transporters breast cancer resistance protein (Bcrp1)/Abcg2 and multidrug resistance-associated protein 2 (Mrp2)/Abcc2. "
2.	Neoplasms (Cancer) 09/01/1999 - "In this study, expression levels of MDR1 and cMOAT were examined in 9 human HCC and HB cell lines and 10 other human cancer cell lines. " 06/01/2010 - "MR images in 25 patients (20 men, five women; mean age, 68 years; range, 49-82 years) with 27 resected hypervascular HCCs (one well, 13 moderately, 13 poorly differentiated) that demonstrated hepatocyte-selective enhancement on gadoxetic acid-enhanced MR images, were quantitatively studied, and findings were correlated with results of immunohistochemical staining for a sinusoidal transporter, organic anion transporting polypeptide (OATP) 1B1 (OATP1B1) and/or OATP1B3 (OATP1B1 and/or -1B3), and a canalicular transporter, multidrug resistance-associated protein 2 (MRP2), and also with bile accumulation in tumors. " 05/01/2002 - "We further found that the expression of multidrug resistance-associated protein 2 (MRP2) in AH66 cells harvested from tumor-bearing rats was markedly decreased after incubation for 48 hours in medium containing 5% fetal bovine serum (5% FBS DMEM), and that the expression recovered when the cells were re-inoculated into rats. " 09/01/1999 - "Therefore, the protein cluster formed by the association of cMOAT, PDZK1, and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance, and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents." 09/01/1999 - "Overexpression of the cMOAT gene was observed in all 9 HCC and HB cell lines and 3 of 10 other cancer cell lines. "
3.	Hepatocellular Carcinoma (Hepatoma) 09/01/1999 - "Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines." 12/01/1998 - "The expression of MRP and cMOAT in the childhood liver tumors was more common and higher, especially in advanced cases with a poor outcome, than that observed in normal liver or in 9 hepatocellular carcinomas from adult patients. " 04/01/2010 - "We hypothesized that expression of multidrug resistance-associated protein 2 (MRP2), a major cisplatin transporter, may determine the efficacy of cisplatin as a treatment for patients with hepatocellular carcinoma (HCC). " 04/01/2010 - "Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma." 05/01/2002 - "Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells."
4.	Cholestasis 02/01/2014 - "We demonstrated that oxidative stress (OS), a key feature in most hepatopathies, induces cholestasis by actin cytoskeleton disarrangement and further endocytic internalization of key canalicular transporters, such as the bile salt export pump (Bsep) and the multidrug resistance-associated protein 2 (Mrp2) . " 06/01/2013 - "Estradiol-17β-D-glucuronide (E17G) induces cholestasis in vivo, endocytic internalization of the canalicular transporters multidrug resistance-associated protein 2 (Abcc2) and bile salt export pump (Abcb11) being a key pathomechanism. " 05/01/2007 - "To explore potent therapeutic agents for cholestasis, the effects of ICKT or its ingredients on multidrug resistance-associated protein 2 (Mrp2/ MRP2)-mediated choleretic activity, as well as on antioxidative action, were investigated using rats and chimeric mice with livers that were almost completely repopulated with human hepatocytes. " 04/01/2004 - "Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2." 03/01/1998 - "The expression of canalicular transporters was differentially regulated in extrahepatic biliary obstruction, indicating the different roles are played by mdr and cMOAT in the pathogenesis of cholestasis."
5.	Hyperbilirubinemia 03/01/1998 - "The biliary excretion mechanism of GPFX was investigated in a series of in vivo and in vitro studies with Sprague-Dawley rats and the mutant strain Eisai-hyperbilirubinemia rats (EHBR), which have a hereditary defect in their bile canalicular multispecific organic anion transport system (cMOAT). " 09/30/1998 - "Elucidation of both the structure of the UGT1 gene complex, and the Mrp2 (cMoat) gene which encodes the canalicular conjugate export pump, has led to a greater understanding of the genetic basis of hyperbilirubinemia." 06/01/1997 - "The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man." 01/01/2009 - "The Dubin-Johnson syndrome (DJS) is an inherited liver disorder characterized by conjugated hyperbilirubinemia and caused by ABCC2 gene mutations resulting in deficiency of multidrug resistance associated-protein 2 (MRP2) function. " 09/28/2006 - "The function of multidrug resistance-associated protein 2 (Mrp2) in the intestine and liver, as well as intestinal Mrp2 expression, was analyzed in CCl(4)-induced acute hepatic failure rats with hyperbilirubinemia. "

Related Drugs and Biologics

1.	Peptides
2.	Carbon Monoxide
3.	Adenosine Triphosphatases (ATPase)
4.	Cisplatin (Platino)
5.	Carrier Proteins (Binding Protein)
6.	Sulindac (Copal)
7.	Probenecid (Benemid)
8.	Bile Acids and Salts (Bile Acids)
9.	10-deazaaminopterin
10.	P-Glycoprotein

Related Therapies and Procedures

1.	Ligation
2.	Intravenous Injections
3.	Drug Therapy (Chemotherapy)
4.	Oral Administration